The ability to reprogram somatic cell nuclei back into a pluripotent epigenetic state provides exciting new possibilities for in vitro research and cell transplantation therapy. There has been a significant quantity of recent research studies demonstrating that this epigenetic reprogramming process is possible with human and non-human primate somatic cells. In this review, various methodologies for reprogramming primate somatic cells into pluripotent stem cells are examined, epigenetic reprogramming following somatic cell nuclear transfer and normal primate embryonic development is compared, and future potential methods to induce direct reprogramming without using genetic modification are discussed.
INTRODUCTION
Every cell in an adult organism, with very few exceptions, contains the same genetic DNA code. Cell fate is dictated by the specific epigenetic code of DNA methylation and histone modifications established during development and cellular differentiation. In this way, early embryonic cells, which are pluripotent (able to form any cell type) become gradually restricted, through epigenetic modifications, to a specific and generally irreversible cell fate. The principle goal of the isogenic pluripotent stem cell (PSC) research field is to reverse or reprogram this differentiated (somatic) epigenetic code back into a pluripotent embryonic stem cell (ESC) like state. Once epigenetically reprogrammed, these isogenic PSCs would be capable of proliferating indefinitely in culture and differentiating into any of the 200 plus cell-types found in the adult body. These PSCs would be isogenic (genetically identical) to the donor individual/patient, so if the patient suffered from a degenerative disease then the differentiated therapeutic derivatives of the isogenic PSCs could theoretically be transferred back into the patient (an autologous transfer or autograft) to cure or alleviate the symptoms of the specific disease without eliciting an immune response (Fig. 1) . Neural precursor cells could be created for patients with spinal cord injury, and dopamine-secreting cells could be created for patients with Parkison's disease. Almost any physical injury or degenerative disease could theoretically be treated in this manner, either directly from isogenic PSC derivatives (1), or following some form of gene therapy to correct the patient's original genetic defect (2,3). Nuclear transfer-derived ESCs have been differentiated into dopaminergic neurons that have alleviated the phenotype of a mouse model of Parkinson's disease (1) , and mice with an immunodeficiency or sickle cell phenotype have been treated with genetically repaired hemotopoietic precursors derived from isogenic PSCs generated through either nuclear transfer (2) or direct reprogramming (3). This isogenic cellular therapy remains the long-term goal of the isogenic PSC field. However, the more immediate benefit from isogenic PSC derivation research would be to generate isogenic PSCs carrying the same genetic defect as a patient with a genetic disease for in vitro research purposes. These disease-specific isogenic PSCs could be used for in vitro research into understanding the mechanisms of poorly understood diseases, drug screening, developmental biology and other forms of basic research. For example, an isogenic PSC line derived from a patient with motor neuron disease could be differentiated into motor neurons in vitro and various drug and chemical combinations could be screened to search for drugs preventing or significantly decreasing the destruction of motor neurons. Both the long-term cellular transplantation and short-term in vitro research applications of isogenic PSCs require that the epigenetic state of the differentiated somatic cell nucleus, which is typically very stable, be fully reprogrammed back into a pluripotent state. There are currently four different methodologies capable, to a greater or lesser extent, of reprogramming primate somatic cell nuclei back into a pluripotent state: cell fusion (4), extract-based reprogramming (5), direct reprogramming (6) and somatic cell nuclear transfer (SCNT) (7).
METHODS FOR REPROGRAMMING SOMATIC CELL NUCLEI
It has been demonstrated both in the mouse (8) and in the human (4) when a differentiated somatic cell is fused with a pluripotent ESC, unknown factors within the pluripotent cell are capable of modifying the epigenetic state of the somatic nucleus back into a pluripotent state, with reactivation of key pluripotency markers such as OCT4, SOX2 and NANOG and differentiation of the somatic/ESC hybrid cells into representatives of all three germ layers following in vivo teratoma formation (4). This fusion-based approach provides an important in vitro research tool and helps in the identification of enhancers of reprogramming. However, the hybrid cells resulting from this fusion-based reprogramming possess both somatic chromosomes and ESC chromosomes, and there is currently no known methodology capable of removing the ESC chromosomal complement, significantly limiting the utilization of the hybrid cells themselves (Fig. 2A) . The second method for reprogramming primate somatic cells involves creating a crude cell extract from a pluripotent population of cells (either embryonic stem or embryonic carcinoma cells) and then transferring this crude extract, with its associated reprogramming factors, directly into the somatic cells. This extract-based reprogramming approach has been used to reprogram human somatic cells to re-express pluripotency markers (5) . However, cells produced in this manner possess only a partially reprogrammed transcriptional state, are not pluripotent and no extract reprogrammed cell has yet demonstrated any in vivo differentiation capacity (Fig. 2B) . The third method for reprogramming a primate somatic cell into a pluripotent epigenetic state involves using virus-mediated transduction to transfer specific reprogramming factors directly into multiple random points throughout the somatic chromatin. The expression of the integrated factors is induced by strong constitutively active promoters to produce large amounts of the reprogramming proteins that over time induce the somatic cell nucleus into a pluripotent epigenetic state via an unknown mechanism. Human somatic cells have been successfully reprogrammed into isogenic PSCs using genetic integration of various factors, combinations of which consistently include OCT4 and SOX2 (6,9 -11) and these directly reprogrammed cells have demonstrated pluripotency with the capacity to differentiate into representatives of all the three germ layers following in vivo teratoma formation. However, isogenic PSCs produced using this direct reprogramming approach require genetic integrations of strongly expressed factors into multiple random locations throughout the genome. This presents a problem, from a therapeutic standpoint, as the initial integration of these factors could potentially inactivate various genes resulting in negative downstream effects, and the possible future reactivation of potentially oncogenic factors, such as OCT4 (12), significantly limits the potential therapeutic applications of these directly reprogrammed isogenic PSCs (Fig. 2C) . While the integration of genetic factors may preclude the usage of directly reprogrammed PSCs for cell transplantation therapies, they would almost certainly be extremely valuable for in vitro applications such as disease research, drug discovery and human genetics. The fourth methodology to reprogram a primate somatic cell nucleus into a pluripotent epigenetic state involves transferring a differentiated nucleus into a metaphase II oocyte (ovum) that has been enucleated (had its DNA either destroyed or removed). The oocyte cytoplasm is capable of epigenetically reprogramming the primate somatic nucleus into a pluripotent state capable of generating teratomas containing representatives of all the three germ layers (7) . The SCNT methodology is the gold standard for epigenetic reprogramming as it produces a PSC that is isogenic to the donor, diploid, fully pluripotent and not genetically modified in any way, making it ideal for both the short-term in vitro research applications and the long-term cellular transplantation options (Fig. 2D) .
SOMATIC CELL NUCLEAR TRANSFER: OOCYTE-BASED REPROGRAMMING
The first demonstration proving that a vertebrate somatic cell nucleus could be reprogrammed back into an embryonic state was in 1962, when John Gurdon transferred the nucleus from a differentiated intestinal epithelial cell into an enucleated Xenopus laevis egg, generating a cloned embryo that developed into a fertile adult frog (13) . This oocyte-based nuclear reprogramming approach was successfully repeated by Ian Wilmut and Keith Campbell with an adult mammalian somatic nucleus in 1997 (14) . To date a large number of animals have been cloned through SCNT (15) and PSCs have been derived from mouse (16), bovine (17) and rabbit (18) SCNT embryos. However, deriving PSCs from primate SCNT embryos proved unachievable with the standard methodologies (19, 20) and it was speculated that biological barriers, specific to the primate, may prevent successful reprogramming following SCNT (20) . Recently, it was demonstrated that a modification to the SCNT methodology-the usage of polarized light during the oocyte enucleation step rather than the usual Hoechst staining and UV visualizationsignificantly improved the rate of SCNT blastocyst formation (21, 22) . It is possible that the UV-based enucleation methodology may be particularly damaging to primate oocytes due to their relative transparency in comparison with similar sized oocytes from other species, including cows, pigs and sheep. Using the modified polarized light SCNT protocol it was demonstrated that fibroblast nuclei derived from an adult rhesus macaque male could be reprogrammed into PSCs following SCNT. The rhesus monkey SCNT-produced PSC lines exhibited a normal ESC morphology, expressed key stem-cell markers, were transcriptionally similar to control ES cells and differentiated into multiple cell types in vitro and in vivo (7). This work succeeded as the first successful nuclear reprogramming of primate somatic cell nuclei into a fully pluripotent epigenetic state.
IMPAIRED EPIGENETIC REPROGRAMMING FOLLOWING SOMATIC CELL NUCLEAR TRANSFER
While it is truly remarkable that the cytoplasmic content of an oocyte is capable of reprogramming a somatic nucleus back into a pluripotent epigenetic state, the efficiency of this reprogramming process is extremely low. In total, 304 primate oocytes were required to produce only two isogenic PSC lines (7) and this low reprogramming efficiency has been demonstrated across all mammalian species cloned to date (23) . There is significant empirical evidence from comparison analysis of primate embryos produced through normal fertilization and SCNT, that in most cases, following nuclear transfer, the somatic nucleus is incompletely reprogrammed to a pluripotent epigenetic state (21, 22, 24) . Following both human and nonhuman primate fertilization, the paternal (sperm) nucleus is actively demethylated by the oocyte cytoplasm during the one cell stage, while the maternal (oocyte) nucleus becomes gradually and passively demethylated through multiple rounds of cell division (24, 25) . On the third day of normal development the primate embryo undergoes embryonic genome activation with a large number of embryonic genes getting significantly expressed at this stage (26) . Between developmental days 5 and 7, the primate embryo divides into a ball of 50-100 cells and forms an inner cavity. This cavitated embryo is referred to as a blastocyst and contains an inner cell mass (ICM) of embryonic cells that express the pluripotency marker OCT4 (27) . It is from these OCT4 positive ICM cells that PSC lines can be derived (28) . Following primate SCNT, the DNA methylation is usually not efficiently removed from the somatic chromatin (24) and on day 3 of embryonic development the primate SCNT embryos typically demonstrate a significantly higher level of DNA methylation and a significantly lower level of histone (H3K9) acetylation, suggesting an impaired embryonic genome activation (24) . The small number of SCNT embryos that do successfully reach the blastocyst stage can still demonstrate an OCT4 expression pattern that is aberrant, reduced or absent (21, 22) , which may explain why the ESC-derivation efficiency from primate SCNT embryos (7) is lower than from fertilized primate embryos (28) . Recent research in the mouse (29) and rabbit (30) has demonstrated that histone acetylation inhibitors such as trichostatin A and sodium butyrate can induce epigenetic modifications that result in an improved developmental efficiency following SCNT (29, 30) . It would be very interesting to discover if these and other epigenetic modification approaches can improve the developmental efficiency following human and non-human primate SCNT. However, even if the efficiency of SCNT is increased, the human SCNT reprogramming methodology is still limited by the requirement for fresh human oocytes and the restricted access to this material. The ideal approach would be to recapitulate the epigenetic reprogramming ability of an oocyte, which can reprogram a somatic cell nucleus without genetically modifying it, without actually requiring the usage of an oocyte, which is limited in supply. The solution to this problem may lie in modifying the human direct reprogramming protocol (6, 9) so that the epigenetic reprogramming processes can occur without genetic modification of the somatic chromatin.
DIRECT REPROGRAMMING: AVOIDING GENETIC INTEGRATION
Recent research has demonstrated in both the mouse (3,31 -33) and the human (6,9 -11) that it is possible to use genetic integration of various factors into somatic cell chromatin to induce the somatic cell to reprogram back into a PSC. These randomly incorporated factors become transcriptionally silenced over time through de-novo DNA methylaton (33) . However, these factors can and do get spontaneously reactivated, resulting in negative downstream effects (32) . Mice derived from PSCs produced though direct reprogramming have a propensity to develop tumors, principally through the re-activation of cMYC (32) . While cMYC itself may not be necessary for reprogramming to occur (10), all current reprogramming protocols still use OCT4, a dose dependent oncogene (12) , and the act of genetic integration itself may inactivate tumor suppressor genes resulting in oncogenesis. The possibility these genetically modified PSCs may become malignant significantly reduces the potential applications of these cells for cell transplantation therapy. Unfortunately, as the integration of the factors is at multiple locations randomly dispersed throughout the genome, direct physical extraction of the integrated factors following the reprogramming process is not possible with current technology. Therefore, the only way to significantly increase the feasibility of isogenic PSCbased therapies would be to reprogram the somatic cells without the initial incorporation of the reprogramming factors into the somatic cell chromatin.
All of the theoretical methodologies for directly reprogramming human somatic cells into PSCs without genetic integration seek to maintain a high level of the various reprogramming proteins within the somatic cell for sufficient time to allow for the reprogramming events to occur. There are currently three general approaches to achieve this: add the reprogramming proteins themselves, add the nucleic acids (DNA or mRNA) coding for the reprogramming proteins or introduce external signals or small molecules capable of activating the expression of the reprogramming proteins. It is not yet clear which of these methodologies will succeed in reprogramming human somatic cells without genetic integration. However, the most similar approach to the current successful direct reprogramming methodology would be the introduction of non-integrated vectors containing the same strongly induced reprogramming factors. While retroviruses and lentiviruses incorporate into the host chromatin, the vast majority of introduced adenoviruses and plasmids do not integrate and remain epichromosomal. These non-integrated epichromosomal vectors utilize the nuclear machinery to continually transcribe and translate the genes they contain, making them ideal for expressing large quantities of the reprogramming proteins inside the transfected cells. The principle disadvantage with the epichromosomal vector approach is that as the cells divide, the vector number per cell decreases, potentially removing or eliminating the expression of the relevant factors before the reprogramming process is complete. One possible solution to this dilution issue is to utilize the serum concentration in the cell culture medium as a variable to control cell division. The concentration of serum in the cell culture medium demonstrates a dose-dependent effect on the cell population doubling time of primary human fibroblasts, with serum concentrations of 10, 4, 2 and 1% giving a respective population doubling time (in hours) of 17.5 + 0.7, 21.5 + 0.5, 28.7 + 1.7 and 57.4 + 10.8 (Byrne, Chang and Reijo Pera, unpublished data) opening up the possibility of using reduced serum concentrations to significantly slow cell growth and thereby reduce the rate at which the non-integrated vectors are diluted through cell division. Additionally, primary human fibroblasts can be induced to stop dividing altogether (enter quiescence) through exposure to a 0.5% serum concentration and those quiescent primary human fibroblasts can be induced to recommence cell division again by re-exposing the cells to higher serum concentrations (Byrne, Chang and Reijo Pera, unpublished data). By using non-dividing quiescent cells, very high intra-cellular concentrations of the reprogramming factors could be produced, potentially increasing the rate of epigenetic reprogramming without factor integration into the chromatin, an exciting, albeit as-of-yet untested hypothesis. When human nuclei are injected into Xenopus oocytes (34) or into mouse myotubes (35) they undergo significant nuclear reprogramming in the absence of DNA replication or cell division, providing supporting evidence for the hypothesis that direct reprogramming of human somatic cell nuclei into a pluripotent epigenetic state may be possible in non-dividing cells.
CONCLUDING STATEMENT
Producing human PSCs genetically identical to a patient generates exciting new possibilities for investigating the mechanisms of disease, drug screening, human genetics, developmental biology and other forms of in vitro research. Once their in vivo safety, functionality and long-term survival is established, it opens the door for allowing these cells to be used for autologous transfer back into the donor patient. Eventually, it may be possible to use human PSCs and their derivatives to replace our cells and regenerate our bodies as they age, mutate and die, allowing us cure our injuries, diseases and disorders, and live longer, healthier lives.
